U.S. markets close in 4 hours 44 minutes

Astellas Pharma Inc. (ALPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
15.700.00 (0.00%)
As of 9:30AM EDT. Market open.
Sign in to post a message.
  • G
    Greg
    Astellas Pharma needs to buy Actinium. Astellas with their market cap of 30Billion this 112 million market cap ATNM is like pocket change and on the edge of major breakthrough! https://www.astellas.com/en/news/16356
    Bullish
  • m
    michael
    Buying on the lows $17.00 by next year
  • S
    Steve
    - Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women - TOKYO , March 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President ...
    - Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women - TOKYO , March 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President ...
    finance.yahoo.com
  • o
    old
    Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but [...]
    Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but [...]
    ipscell.com
  • J
    Jim
    Ocata shareholders: Aren't you glad you bought into this?
  • H
    Haley
    This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ... Great article here about ALPMF https://marketwirenews.com/news-releases/a-20-billion-sweet-spot-in-biotech-4952829704472218.html?i=y
    This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech.
    This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech.
    marketwirenews.com
  • N
    Neanderthal thinking
    European and U.S. equity futures fell sharply on Wednesday, in a weak start for the new quarter after experts predicted a staggering 100,000 to 240,000 U.S. deaths even after adhering to social distancing guidelines.
    The Stoxx Europe 600 index SXXP, -3.253% fell over 3% to 309.41, after gaining 1.6% to 320.06 on Tuesday. It closed out the first quarter with a 23% loss, its biggest since the third quarter of 2002. The German DAX DAX, -3.675% slid 3.3%, while the French CAC 40 PX1, -3.973% and the FTSE 100 UKX, -4.224% dropped around 4% each.
  • N
    Neanderthal thinking
    Breakout stock today ; ZSAN
    200% spike yesterday could bring this 3 million float Stock fllying 2 digits. Life time opportunity make 💰 💰
  • m
    michael
    great days are coming 2019 in the thirties
  • J
    Jim
    What's happening with OCATA's AMD trial??
  • P
    PS
    Why is this at a 52 Week low ?
  • .
    ...
    I still don't see any news out. What is driving today's price spike?
  • B
    Bob
    there is some news out today re: alpmy concerning ocat's stem cells.
  • m
    michael
    Why the big jump today ?
  • m
    michael
    Great move by alpmy buy while it's still cheap. One day soon a great jump in value IMO
  • n
    ninerjd
    Why the recent spike in price and volume?
  • J
    JJM
    Pfizer Inc.
    Pfizer and Astellas' Xtandi successful in late-stage prostate cancer study https://seekingalpha.com/news/3432026?source=ansh $PFE, $ALPMF
    Results from a Phase 3 clinical trial, ARCHES, evaluating Pfizer (NYSE:PFE) and Astellas Pharma's (OTCPK:ALPMF) XTANDI (enzalutamide) plus standard hormonal therapy in men with metastatic hormone-sens
    Results from a Phase 3 clinical trial, ARCHES, evaluating Pfizer (NYSE:PFE) and Astellas Pharma's (OTCPK:ALPMF) XTANDI (enzalutamide) plus standard hormonal therapy in men with metastatic hormone-sens
    seekingalpha.com
  • m
    michael
    This should double within two yrs.
  • R
    Really
    Analysts that like PFE ought to like ALPMY, as well.
  • S
    Shawna
    Cytokinetics-Astellas Partnership Raised to Another Level in $95M Deal | GEN News Highlights | GEN
    Get the latest in biotechnology through daily news coverage as well as analysis, features, tutorials, webinars, podcasts, and blogs. Learn about the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, a
    www.genengnews.com